SSMXF Stock Chart & Stats
$9.14
$0.00(0.00%)
At close: 4:00 PM EST
$9.14
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$7.76 - $17.52
Previous CloseN/A
Volume78.00
Average Volume (3M)121.00
Market Cap
$5.64B
Enterprise Value$855.49B
Total Cash (Recent Filing)$84.12B
Total Debt (Recent Filing)$70.48B
Price to Earnings (P/E)26.2
Beta-0.08
Next Earnings
Aug 11, 2026EPS Estimate
0.06Next Dividend Ex-DateN/A
Dividend Yield2.27%
Share Statistics
EPS (TTM)56.89
Shares Outstanding629,480,100
10 Day Avg. Volume306
30 Day Avg. Volume121
Financial Highlights & Ratios
PEG Ratio-0.71
Price to Book (P/B)1.69
Price to Sales (P/S)1.71
P/FCF Ratio20.83
Enterprise Value/Market Cap151.80
Enterprise Value/Revenue1.71
Enterprise Value/Gross Profit3.35
Enterprise Value/Ebitda8.57
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.41
Revenue Forecast (FY)$3.35B
Bulls Say, Bears Say
Bulls Say
Recurring Consumables And Service RevenuesSysmex's core business combines capital instrument placements with high-margin recurring consumables and multi-year service contracts. This installed-base model creates durable, usage-linked revenue and visibility: each instrument drives ongoing reagent and service demand, anchoring long-term cash flows and customer stickiness.
Conservative Balance Sheet And Equity GrowthA sizable and expanding equity base with historically low leverage provides substantial financial flexibility. This capital conservatism supports R&D, product upgrades, and cyclical resilience, allowing the company to fund growth, absorb shocks, and pursue M&A or capex without immediate refinancing pressure.
Sustainably Healthy Gross And Net MarginsConsistently high gross margins reflect favorable product mix (instruments plus consumables) and pricing power in diagnostics. Stable net margins show operational discipline. These margin levels support recurring profitability, enabling reinvestment and dividend capacity even through moderate top-line swings.
Bears Say
Sharp 2026 Revenue And Profit DeteriorationA meaningful step-down in revenue and operating profit in 2026 signals that prior growth drivers weakened. If structural (lower placements, reimbursement or market demand shifts), this could compress margins, reduce reagent pull-through and limit free-cash-flow, challenging near-term investment and dividend plans.
Rising Total Debt TrendAlthough leverage remains modest, the rising debt trajectory reduces optionality if earnings weaken further. Higher interest or principal obligations limit capital allocation flexibility, could force prioritization of liabilities over growth projects, and increases refinancing risk if market conditions tighten.
Volatile Free Cash Flow And Uneven Cash ConversionIrregular FCF and inconsistent cash conversion point to working-capital swings or lumpy investments. This variability complicates reliable funding for R&D, capex, and shareholder returns; persistent volatility would force more conservative payout and investment policies, slowing long-term strategic execution.
Sysmex News
SSMXF FAQ
What was Sysmex Corporation’s price range in the past 12 months?
Sysmex Corporation lowest stock price was $7.76 and its highest was $17.52 in the past 12 months.
What is Sysmex Corporation’s market cap?
Sysmex Corporation’s market cap is $5.64B.
When is Sysmex Corporation’s upcoming earnings report date?
Sysmex Corporation’s upcoming earnings report date is Aug 11, 2026 which is in 40 days.
How were Sysmex Corporation’s earnings last quarter?
Sysmex Corporation released its earnings results on May 14, 2026. The company reported $0.017 earnings per share for the quarter, missing the consensus estimate of $0.036 by -$0.019.
Is Sysmex Corporation overvalued?
According to Wall Street analysts Sysmex Corporation’s price is currently Overvalued.
Does Sysmex Corporation pay dividends?
Sysmex Corporation pays a Semiannually dividend of $0.122 which represents an annual dividend yield of 2.27%. See more information on Sysmex Corporation dividends here
What is Sysmex Corporation’s EPS estimate?
Sysmex Corporation’s EPS estimate is 0.06.
How many shares outstanding does Sysmex Corporation have?
Sysmex Corporation has 629,480,100 shares outstanding.
What happened to Sysmex Corporation’s price movement after its last earnings report?
Sysmex Corporation reported an EPS of $0.017 in its last earnings report, missing expectations of $0.036. Following the earnings report the stock price went down -1.746%.
Which hedge fund is a major shareholder of Sysmex Corporation?
Currently, no hedge funds are holding shares in SSMXF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Sysmex Corporation
Sysmex Corporation, headquartered in Kobe, Japan, and established in 1968 (originally known as TOA Medical Electronics Co., Ltd. until its rebranding in October 1998), specializes in the development, manufacturing, and global distribution of advanced diagnostic instrumentation, chemical reagents, and associated software. Its comprehensive product portfolio addresses various diagnostic needs. In hematology, it offers instruments for both three-part and five-part white blood cell differentiation, alongside efficient transport systems designed for high-volume laboratory testing. For urinalysis, the company provides systems capable of analyzing urine formed sediment. Its offerings extend to automated immunochemistry systems, which are adept at performing assays with minute sample quantities, complemented by reagents for detecting infectious diseases and tumor markers. Sysmex also manufactures flow cytometers, crucial for the analysis involved in diagnosing conditions such as leukemia, malignant lymphoma, and HIV/AIDS. Beyond these core areas, the company is deeply involved in oncology diagnostics, developing systems for detecting cancer lymph node metastasis and cancer genome profiling, as well as offering cytogenetic testing and specialized lab assay services. Sysmex also contributes to digital medicine through the development and sale of software for diagnostic information systems, alongside the creation, operation, and maintenance of IT solutions, platforms, and applications in this field. Its activities further encompass the development and sale of nucleic acid analogs, the full lifecycle management (marketing, development, design, manufacture, sale, and after-sales support) of medical robots, and the distribution and post-sales support for medical devices and reagents used in biotechnology, medical technology, and molecular cell analysis. Sysmex serves a diverse client base, including national, public, and private hospitals, universities, research institutes, and other medical facilities. With a robust international presence, the company exports its products to approximately 190 countries worldwide. Demonstrating its commitment to innovation, Sysmex Corporation maintains a strategic alliance with QIAGEN N.V. for the collaborative development and commercialization of cancer companion diagnostics utilizing Plasma-Safe-SeqS technology.
Technical Analysis
Ownership Overview
―
Insiders
7.12% Mutual Funds
<0.01% Other Institutional Investors
87.55% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---